Follow
Gang (Gerry) Li
Gang (Gerry) Li
Alexion, AstraZeneca Rare Disease
No verified email
Title
Cited by
Cited by
Year
Bacterial cupredoxin azurin as an inducer of apoptosis and regression in human breast cancer
V Punj, S Bhattacharyya, D Saint-Dic, C Vasu, EA Cunningham, J Graves, ...
Oncogene 23 (13), 2367-2378, 2004
2022004
Nonparametric multiple comparison procedures for unbalanced one-way factorial designs
X Gao, M Alvo, J Chen, G Li
Journal of Statistical Planning and Inference 138 (8), 2574-2591, 2008
1182008
D-optimal designs for logistic models with three and four parameters
G Li, D Majumdar
Journal of Statistical Planning and Inference 138 (7), 1950-1959, 2008
672008
On sample size calculation based on odds ratio in clinical trials
H Wang, SC Chow, G Li
Journal of Biopharmaceutical Statistics 12 (4), 471-483, 2002
472002
Systematic review and meta-analysis of antimicrobial treatment effect estimation in complicated urinary tract infection
KP Singh, G Li, FS Mitrani-Gold, M Kurtinecz, J Wetherington, JF Tomayko, ...
Antimicrobial agents and chemotherapy 57 (11), 5284-5290, 2013
372013
Phase 1 dose‐escalating study to evaluate the safety, pharmacokinetics, and pharmacodynamics of a recombinant factor Xa variant (FXaI16L)
D Parsons‐Rich, F Hua, G Li, C Kantaridis, DD Pittman, S Arkin
Journal of Thrombosis and Haemostasis 15 (5), 931-937, 2017
302017
Topical retapamulin in the management of infected traumatic skin lesions
R Shawar, N Scangarella-Oman, MB Dalessandro, J Breton, M Twynholm, ...
Therapeutics and Clinical Risk Management, 41-49, 2009
272009
Some results on D-optimal designs for nonlinear models with applications
G Li, D Majumdar
Biometrika 96 (2), 487-493, 2009
232009
Optimal designs for tumor regrowth models
G Li, N Balakrishnan
Journal of Statistical Planning and Inference 141 (2), 644-654, 2011
192011
A group sequential type design for three‐arm non‐inferiority trials with binary endpoints
G Li, S Gao
Biometrical journal 52 (4), 504-518, 2010
172010
A randomized, double-blind, comparative study to assess the safety and efficacy of topical retapamulin ointment 1% versus oral linezolid in the treatment of secondarily …
T Tanus, NE Scangarella-Oman, M Dalessandro, G Li, JJ Breton, ...
Advances in skin & wound care 27 (12), 548-559, 2014
152014
Optimal and efficient designs for Gompertz regression models
G Li
Annals of the Institute of Statistical Mathematics 64, 945-957, 2012
152012
Systematic review
MK Wang, R Heo, PB Meyre, S Blum, L Park, L Birchenough, K Vuong, ...
Clinical ethics, 2023
10*2023
The safety and efficacy of topical retapamulin ointment versus placebo ointment in the treatment of secondarily infected traumatic lesions: a randomized, double-blind …
JF Tomayko, G Li, JJ Breton, N Scangarella-Oman, MB Dalessandro, ...
Advances in skin & wound care 26 (3), 113-121, 2013
82013
Phase 1b study to evaluate safety, tolerability, and maximum tolerated dose of PF-05230907 for intracerebral hemorrhage
Y Silva Blas, MN Diringer, B Lo, J Masjuan, N Pérez de la Ossa, ...
Stroke 52 (1), 294-298, 2021
52021
Phase 3 adaptive trial design options in treatment of complicated urinary tract infection
K Viele, LM Mundy, RB Noble, G Li, K Broglio, JD Wetherington
Pharmaceutical Statistics 17 (6), 811-822, 2018
32018
Escalating single doses of PF-05230907 (recombinant factor Xa variant FXaI16L) are safe and demonstrate hemostatic pharmacology in healthy volunteers
S Arkin, F Hua, C Kantaridis, G Li, D Parsons-Rich, DD Pittman
Blood 128 (22), 3781, 2016
32016
SINGLE-DOSE PHARMACOKINETICS OF RETAPAMULIN IN YOUNG CHILDREN WITH UNCOMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS.
JZ Zhu, M Dalessandro, R Paternoster, G Li, J Tomayko
CLINICAL PHARMACOLOGY & THERAPEUTICS 87, S12-S13, 2010
2010
Molecular characterisation of meticillin-resistant Staphylococcus aureus nasal isolates from patients with uncomplicated skin infections: P935
R Shawar, N Scangarella, G Li, M Twynholm, M Dalessandro, J Breton, ...
Clinical Microbiology & Infection 14, 2008
2008
Comparative antibacterial activity of retapamulin, cephalothin, gentamicin and erythromycin against Staphylococcus aureus, including molecularly characterised isolates of MRSA …
N Scangarella, R Shawar, G Li, M Twynholm, M Dalessandro, J Breton, ...
Clinical Microbiology & Infection 14, 2008
2008
The system can't perform the operation now. Try again later.
Articles 1–20